 <h1>Brentuximab Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>More frequently reported side effects include:</b> peripheral motor neuropathy.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to brentuximab: intravenous powder for solution</i></p><h3>Warning</h3><p class="blackboxWarning-title">Intravenous route (Powder for Solution)</p><p>John Cunningham (JC) virus infection resulting in progressive multifocal leukoencephalopathy (PML) and death can occur in patients receiving brentuximab vedotin.</p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, brentuximab may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<i>Check with your doctor or nurse immediately</i> if any of the following side effects occur while taking brentuximab:</p><p>
<i>More common</i>
</p><ul>
<li>Abdominal or stomach pain</li>
<li>back pain</li>
<li>black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>blurred vision</li>
<li>body aches or pain</li>
<li>bone pain</li>
<li>burning, numbness, tingling, or painful sensations</li>
<li>chills</li>
<li>cough</li>
<li>difficult or labored breathing</li>
<li>dry mouth</li>
<li>ear congestion</li>
<li>fever</li>
<li>flushed, dry skin</li>
<li>fruit-like breath odor</li>
<li>headache</li>
<li>increased hunger</li>
<li>increased thirst</li>
<li>increased urination</li>
<li>loss of voice</li>
<li>lower back or side pain</li>
<li>nausea</li>
<li>pain</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>sneezing</li>
<li>sore throat</li>
<li>stuffy or runny nose</li>
<li>sweating</li>
<li>swollen, painful, or tender lymph glands in the neck, armpit, or groin</li>
<li>tightness in the chest</li>
<li>troubled breathing with exertion</li>
<li>unexplained weight loss</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unsteadiness or awkwardness</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
<li>vomiting</li>
<li>weakness in the arms, hands, legs, or feet</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Anxiety</li>
<li>bladder pain</li>
<li>blistering, peeling, or loosening of the skin</li>
<li>bloating or swelling of the face, arms, hands, lower legs, or feet</li>
<li>chest pain</li>
<li>cloudy urine</li>
<li>confusion</li>
<li>diarrhea</li>
<li>dizziness or lightheadedness</li>
<li>drowsiness</li>
<li>fainting</li>
<li>fast heartbeat</li>
<li>frequent urge to urinate</li>
<li>general feeling of discomfort or illness</li>
<li>irregular heartbeat</li>
<li>itching</li>
<li>joint pain, stiffness, or swelling</li>
<li>muscle pain</li>
<li>rapid weight gain</li>
<li>red skin lesions, often with a purple center</li>
<li>red, irritated eyes</li>
<li>seizures</li>
<li>severe pain in the chest</li>
<li>sudden onset of severe breathing difficulty</li>
<li>thickening of bronchial secretions</li>
<li>unusual weight gain or loss</li>
</ul><p>
<i>Incidence not known</i>
</p><ul>
<li>Clay-colored stools</li>
<li>dark urine</li>
<li>heartburn</li>
<li>indigestion</li>
<li>severe abdominal pain, cramping, or burning</li>
<li>severe constipation</li>
<li>severe vomiting</li>
<li>vomiting of material that looks like coffee grounds</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of brentuximab may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Decreased appetite or weight</li>
<li>difficulty having a bowel movement</li>
<li>difficulty with moving</li>
<li>hair loss or thinning of the hair</li>
<li>muscle spasm or stiffness</li>
<li>night sweats</li>
<li>pain in the arms or legs</li>
<li>rash</li>
<li>trouble sleeping</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Dry skin</li>
</ul><p>
<!-- end intravenous powder for solution --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to brentuximab: intravenous powder for injection</i></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 31%), pruritus (up to 19%), alopecia (up to 14), night sweats (up to 12%), dry skin (up to 10%)</p>
<p><b>Rare</b> (less than 0.1%): : Stevens-Johnson syndrome (SJS) (including fatal outcomes), toxic epidermal necrolysis (including fatal outcomes)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 42%), diarrhea (up to 36%), abdominal pain (up to 25%), vomiting (up to 22%), constipation (up to 19%)</p>
<p><b>Postmarketing reports</b>: Pancreatitis (including fatal outcomes)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia (any grade) (up to 78%), anemia (up to 52%), thrombocytopenia (up to 41%), lymphadenopathy (up to 11%)</p>
<p><b>Postmarketing reports</b>: Febrile neutropenia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Anaphylactic reaction<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Weight decreased (up to 19%), decreased appetite (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Hyperglycemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (up to 19%), myalgia (up to 17%), back pain (up to 14%), pain in extremity (up to 10%)</p>
<p><b>Common</b> (1% to 10%): Muscle spasms<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Peripheral sensory neuropathy (up to 56%), peripheral motor neuropathy (up to 23%), headache (up to 19%), dizziness (up to 16%)</p>
<p><b>Common</b> (1% to 10%): Demyelinating polyneuropathy</p>
<p><b>Frequency not reported</b>: Progressive multifocal leukoencephalopathy<sup>[Ref]</sup></p><h3>Other</h3><p>Other side effects have included infusion related reactions (12%) including chills, nausea, dyspnea, pruritus, pyrexia and cough.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (up to 16%), anxiety (up to 11%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory infection (up to 47%), cough (up to 25%), dyspnea (up to 17%), oropharyngeal pain (up to 11%)</p>
<p><b>Postmarketing reports</b>: Noninfectious pulmonary toxicity (including fatal outcomes)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Alanine aminotransferase/aspartate aminotransferase (ALT/AST) increased</p>
<p><b>Postmarketing reports</b>: Hepatotoxicity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection</p>
<p><b>Common</b> (1% to 10%): Sepsis/septic shock, pneumonia, herpes zoster</p>
<p><b>Uncommon</b> (0.1% to 1%): Oral candidiasis, pneumocystis jiroveci pneumonia, staphylococcal bacteremia</p>
<p><b>Postmarketing reports</b>: Serious opportunistic infections<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Tumor lysis syndrome<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_3">3. "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about brentuximab</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: CD30 monoclonal antibodies</li>
<li>FDA Alerts (1)</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Brentuximab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Adcetris</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Hodgkin's Lymphoma</li>
<li>Lymphoma</li>
<li>Mycosis Fungoides</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to brentuximab: intravenous powder for injection</i></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 31%), pruritus (up to 19%), alopecia (up to 14), night sweats (up to 12%), dry skin (up to 10%)</p><p><b>Rare</b> (less than 0.1%): : Stevens-Johnson syndrome (SJS) (including fatal outcomes), toxic epidermal necrolysis (including fatal outcomes)<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Nausea (up to 42%), diarrhea (up to 36%), abdominal pain (up to 25%), vomiting (up to 22%), constipation (up to 19%)</p><p><b>Postmarketing reports</b>: Pancreatitis (including fatal outcomes)<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Neutropenia (any grade) (up to 78%), anemia (up to 52%), thrombocytopenia (up to 41%), lymphadenopathy (up to 11%)</p><p><b>Postmarketing reports</b>: Febrile neutropenia<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Frequency not reported</b>: Anaphylactic reaction<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Weight decreased (up to 19%), decreased appetite (up to 11%)</p><p><b>Common</b> (1% to 10%): Hyperglycemia<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (up to 19%), myalgia (up to 17%), back pain (up to 14%), pain in extremity (up to 10%)</p><p><b>Common</b> (1% to 10%): Muscle spasms<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Peripheral sensory neuropathy (up to 56%), peripheral motor neuropathy (up to 23%), headache (up to 19%), dizziness (up to 16%)</p><p><b>Common</b> (1% to 10%): Demyelinating polyneuropathy</p><p><b>Frequency not reported</b>: Progressive multifocal leukoencephalopathy<sup>[Ref]</sup></p><h3>Other</h3><p>Other side effects have included infusion related reactions (12%) including chills, nausea, dyspnea, pruritus, pyrexia and cough.<sup>[Ref]</sup></p><h3>Psychiatric</h3><p><b>Very common</b> (10% or more): Insomnia (up to 16%), anxiety (up to 11%)<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Upper respiratory infection (up to 47%), cough (up to 25%), dyspnea (up to 17%), oropharyngeal pain (up to 11%)</p><p><b>Postmarketing reports</b>: Noninfectious pulmonary toxicity (including fatal outcomes)<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Common</b> (1% to 10%): Alanine aminotransferase/aspartate aminotransferase (ALT/AST) increased</p><p><b>Postmarketing reports</b>: Hepatotoxicity<sup>[Ref]</sup></p><h3>Immunologic</h3><p><b>Very common</b> (10% or more): Infection</p><p><b>Common</b> (1% to 10%): Sepsis/septic shock, pneumonia, herpes zoster</p><p><b>Uncommon</b> (0.1% to 1%): Oral candidiasis, pneumocystis jiroveci pneumonia, staphylococcal bacteremia</p><p><b>Postmarketing reports</b>: Serious opportunistic infections<sup>[Ref]</sup></p><h3>Oncologic</h3><p><b>Uncommon</b> (0.1% to 1%): Tumor lysis syndrome<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp."   ([2006]):</p><p id="ref_3">3. "Product Information. Adcetris (brentuximab vedotin)." Seattle Genetics Inc, Bothell, WA. </p><h2>More about brentuximab</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Espa√±ol</li>
<li>Drug class: CD30 monoclonal antibodies</li>
<li>FDA Alerts (1)</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Brentuximab Intravenous &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Hodgkin's Lymphoma</li>
<li>Lymphoma</li>
<li>Mycosis Fungoides</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>